GSE172016 paclitaxel 2 v 5 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE172016_paclitaxel_2_v_5_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE172016_paclitaxel_2_v_5_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE172016_paclitaxel_2_v_5_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE172016_paclitaxel_2_v_5_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

H19 imprinted maternally expressed transcript

Gene

small nucleolar RNA host gene 16

Gene

double homeobox A pseudogene 8

Gene

MIR1915 host gene

Gene

VPS9D1 antisense RNA 1

Gene

urothelial cancer associated 1

Gene

long intergenic non-protein coding RNA 1963

Gene

long intergenic non-protein coding RNA 1106

Gene

long intergenic non-protein coding RNA 1234

Gene

long intergenic non-protein coding RNA 632

  • Gene

    H19 imprinted maternally expressed transcript


  • Gene

    small nucleolar RNA host gene 16


  • Gene

    double homeobox A pseudogene 8



  • Gene

    VPS9D1 antisense RNA 1


  • Gene

    urothelial cancer associated 1


  • Gene

    long intergenic non-protein coding RNA 1963


  • Gene

    long intergenic non-protein coding RNA 1106


  • Gene

    long intergenic non-protein coding RNA 1234


  • Gene

    long intergenic non-protein coding RNA 632

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.